Update: Direct oral anticoagulants (DOAC) – their use and clinical management remain a challenge

• References

• 1 Voigtlaender M, Langer F. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism – what do we know so far?. Hämostaseologie 2017; 37: 241-255.
• 2 Lindhoff-Last E. Direct oral anticoagulants – Management of emergency situations – Rationale and design of the RADOA-registry. Hämostaseologie 2017; 37: 257-266.
• 3 Koscielny J, Rosenthal C, von Heymann C. Update on direct oral anticoagulants: perioperative “switching”, drug interactions and persistence. Hämostaseologie 2017; 37: 267-275.
• 4 Benetos G, Bonou M, Toutouzas K, Diamantopoulos P, Viniou N, Barbetseas J. Advances in antico-Prof. Dr. Edelgard Lindhoff-Last Cardioangiology Center Bethanien Hospital (CCB), CCB Vascular Center, CCB Coagulation Center, CCB Coagulation Research Center, Frankfurt, Germany agulation management of patients undergoing cardioversion of nonvalvular atrial fibrillation. Hämostaseologie 2017; 37: 277-285.
• 5 Kücükköylü S, Rump LC. Update Direct oral anticoagulants – use in patients with chronic kidney disease with or without dialysis. Hämostaseologie 2017; 37: 286-294.
• 6 Gosselin RC, Douxfils J, Adcock D. Clinical perls: Laboratory assessment of direct oral anticoagulants. Hämostaseologie 2017; 37: 295-301.
• 7 Göndör G, Stöllberger C. Pulmonary embolism four days after interruption of therapy with rivaroxaban. Hämostaseologie 2017; 37: 302-306.
• 8 Konstantinides SV. The risks of interrupting anticoagulation. Hämostaseologie 2017; 37: 239-240.